Cinacalcet Tablets
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
166 recalls, newest first
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Failed Impurities/Degradation Specifications.
Presence of Particulate Matter: Presence of glass particulates.
cGMP violations
cGMP violations
cGMP violations
cGMP violations
cGMP violations
cGMP violations
cGMP violations
cGMP violations
CGMP violations
Presence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.
Presence of Particulate Matter: Presence of glass particle.
Microbial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.
Temperature abuse: Products exposed to improper temperature above drug label specifications.
cGMP Deviations: Temperature excursion
Lack of Assurance of Sterility
Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.
LABELING: LABEL MIX-UP.
Defective Delivery System: incorrect silicone oil-free NormJect 10 mL Luer Lock Solo syringes packaged in the pack, instead of the required silicone oil-free NormJect 10 mL Luer Solo syringes (luer slip connection).
Lack of Assurance of Sterility